Gary Pestano Biography and Net Worth

Chief Scientific Officer of Biodesix

Gary Pestano, Ph.D. is a development leader in assays and products of high complexity molecular diagnostics in oncology and virology, including genomic and proteomic technologies. In addition to serving as the Chief Scientific Officer and the head of R&D at Biodesix, Gary is the NYS Laboratory Director of the company’s CLEP | CLIA | ISO13485-certified laboratory in Colorado.

Prior to joining Biodesix in 2012, Dr. Pestano led multidisciplinary teams in the development of multiplexed tissue and cell-based diagnostic assays, cancer vaccines and scientific modeling software. He held senior positions in Discovery, Development, Pharma Services, and global Project Leadership at Ventana, a member of the Roche Group.

Dr. Pestano is the co-inventor on multiple national and international patents including for novel devices and detection systems for nucleic acid, cell, and tissue diagnostics. He has also fostered many collaborations at leading academic centers, academic/industry consortia, and in the biotechnology industry as a part of both R&D and new product development.

Dr. Pestano received his Ph.D. training in Cell and Molecular Biology at The Graduate Center, City University of New York and conducted his post-doctoral training in cancer immunology at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Pestano holds advanced training certificates from Harvard Business School, MIT, and the University of London.

What is Gary Anthony Pestano's net worth?: The estimated net worth of Gary Anthony Pestano is at least $249.55 thousand as of February 23rd, 2026. Dr. Pestano owns 10,359 shares of Biodesix stock worth more than $249,548 as of July 1st. This net worth estimate does not reflect any other assets that Dr. Pestano may own. Learn More about Gary Anthony Pestano's net worth.
How do I contact Gary Anthony Pestano?: The corporate mailing address for Dr. Pestano and other Biodesix executives is , , . Biodesix can also be reached via phone at 303-417-0500 and via email at [email protected]. Learn More on Gary Anthony Pestano's contact information.
Has Gary Anthony Pestano been buying or selling shares of Biodesix?: Gary Anthony Pestano has not been actively trading shares of Biodesix during the past quarter. Most recently, Gary Anthony Pestano sold 556 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $12.78, for a transaction totalling $7,105.68. Following the completion of the sale, the insider now directly owns 10,359 shares of the company's stock, valued at $132,388.02. Learn More on Gary Anthony Pestano's trading history.
Who are Biodesix's active insiders?: Biodesix's insider roster includes Robin Cowie (CFO), Scott Hutton (CEO), John Patience (Chairman), Gary Pestano (Chief Scientific Officer), Jack Schuler (Director), and Charles Watts (Director). Learn More on Biodesix's active insiders.
Are insiders buying or selling shares of Biodesix?: During the last twelve months, Biodesix insiders bought shares 7 times. They purchased a total of 517,301 shares worth more than $4,695,978.20. During the last twelve months, insiders at the sold shares 25 times. They sold a total of 11,592 shares worth more than $120,842.31. The most recent insider tranaction occured on February, 23rd when insider Gary Anthony Pestano sold 556 shares worth more than $7,105.68. Insiders at Biodesix own 23.2% of the company. Learn More about insider trades at Biodesix.
Information on this page was last updated on 2/23/2026.

Gary Anthony Pestano Insider Trading History at Biodesix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/23/2026	Sell	556	$12.78	$7,105.68	10,359
2/10/2026	Sell	540	$10.08	$5,443.20	9,387
1/16/2026	Sell	298	$8.15	$2,428.70	8,446
11/10/2025	Sell	23	$7.62	$175.26	7,939
8/13/2025	Sell	22	$8.40	$184.80	7,893
5/12/2025	Sell	11	$7.20	$79.20	7,858
2/11/2025	Sell	837	$18.40	$15,400.80	7,800
8/12/2024	Sell	5	$31.40	$157.00	6,303
8/9/2024	Sell	16	$32.00	$512.00	6,309
5/9/2024	Sell	21	$29.60	$621.60	6,212
2/12/2024	Sell	251	$33.20	$8,333.20	6,162
2/9/2024	Sell	293	$38.40	$11,251.20	6,413
11/9/2023	Sell	10	$25.40	$254.00	5,235
8/9/2023	Sell	39	$27.80	$1,084.20	5,217
2/9/2023	Sell	92	$36.00	$3,312.00	4,796

Gary Anthony Pestano Buying and Selling Activity at Biodesix

Biodesix Company Overview

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Today's Range

Now: $24.08

$21.88

$24.71

50 Day Range

MA: $15.27

$9.84

$23.81

2 Week Range

Now: $24.08

$5.26

$24.71

Volume

92,604 shs

Average Volume

759,466 shs

Market Capitalization

$249.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59